Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤EQ504 Phase 1 trial initiated; topline proof-of-mechanism data expected Q2 2027
- ➤Equillium raised approximately $20 million in October financing
- ➤Cash balance approximately $72.0 million pro forma; runway expected into 2029
- ➤Third-quarter net loss $4.6 million, or $(0.04) per share
- ➤R&D expenses rose to $2.5 million from $1.3 million year over year
Expert Statements
Bruce Steel, Chief Executive Officer of Equillium
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program.”
Bruce Steel, Chief Executive Officer of Equillium
“We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.”
Bruce Steel, Chief Executive Officer of Equillium
“We look forward to reporting proof-of-mechanism data in the second quarter of 2027, which we expect will inform our planned proof-of-concept study in ulcerative colitis that we expect to initiate in the second half of 2027.”
Bruce Steel, Chief Executive Officer of Equillium
“Supported by our strong financial position, we remain focused on advancing EQ504 to patients while continuing to evaluate its broader therapeutic potential.”
First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027
Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026
Get started
Create a free account to read the full story.